Journal of Rheumatic Diseases最新文献

{"title":"Characterising axial psoriatic arthritis in clinical practice: a retrospective analysis from the Rheumatic Diseases Portuguese Registry.","authors":"Catarina Abreu, Vanessa Fraga, Inês Almeida, Mariana Diz Lopes, Sofia Azevedo, Carolina Vilafanha, João Rovisco, Maria Pontes Ferreira, Hugo Parente, Anita Cunha, Catarina Dantas Soares, Dina Medeiros, Duarte Augusto, Mariana Rocha Sebastião, Lígia Silva, Tiago Meirinhos, Joana Dinis, Filipe Araújo, José Tavares-Costa, António Vilar, Alice Morais Castro, Maria José Santos","doi":"10.4078/jrd.2025.0149","DOIUrl":"10.4078/jrd.2025.0149","url":null,"abstract":"<p><strong>Objective: </strong>To determine the proportion of axial psoriatic arthritis (axPsA), describe how it is diagnosed in clinical practice, and identify clinical and demographic characteristics independently associated with axPsA.</p><p><strong>Methods: </strong>A multicentre retrospective observational study was conducted using data from patients registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt) with a diagnosis of PsA or spondyloarthritis with psoriasis. Peripheral involvement was defined as the presence of peripheral joint disease. Axial involvement was defined by the presence of physician-reported spondylitis and/or imaging findings suggestive of axial disease. Patients were divided into four non-exclusive groups axPsA, axial involvement with or without peripheral joint disease; ax-PsA_only, axial involvement exclusively; peripheral PsA (pPsA)_only, peripheral joint disease, without axial involvement; pPsA, peripheral joint disease with or without axial disease.</p><p><strong>Results: </strong>This study included 2,304 patients. axPsA was present in 37.1% of patients and axPsA_only in 8.1%. The diagnosis was made based on suggestive imaging findings in 30.1%, and on physician judgement in 69.9%. axPsA was independently associated with HLA-B27 positivity (odds ratio [OR]=2.90; p<0.001), enthesitis (OR=1.64; p<0.001), and younger age at symptom onset (OR=0.97; p<0.001); pPsA_only with dactylitis (OR=1.89; p<0.001) and nail dystrophy (OR=1.42; p=0.010). axPsA_only was independently associated HLA-B27 positivity (OR=3.35; p<0.001) and uveitis (OR=2.56; p=0.004); pPsA with nail dystrophy (OR=2.11; p=0.002), dactylitis (OR=18.18; p<0.001), and enthesitis (OR=1.74; p=0.031).</p><p><strong>Conclusion: </strong>Axial involvement is present in over one-third of PsA patients, often in association with peripheral joint disease. axPsA patients demonstrate distinct clinical and demographic characteristics compared to those without axial disease.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"304-314"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Korean College of Rheumatology treatment recommendations for patients with axial spondyloarthritis: 2026 update.","authors":"Hong Ki Min, Mi Ryoung Seo, Sang-Hoon Lee, Yeon-Ah Lee, Jennifer Jooha Lee, Seong-Ryul Kwon, Tae-Hwan Kim, Min-Chan Park, Kichul Shin, Ji Hyeon Ju, Yong-Gil Kim, Bon San Koo, Eun Young Lee, Hoon-Suk Cha, Seung Cheol Shim, Ji Hui Shin, Tae-Jong Kim","doi":"10.4078/jrd.2026.0126","DOIUrl":"10.4078/jrd.2026.0126","url":null,"abstract":"<p><p>We aimed to develop updated evidence-based recommendations for the management of adult patients with axial spondyloarthritis (axSpA) in Korea. The Korean College of Rheumatology convened a multidisciplinary panel to update the 2023 axSpA guideline. Twenty key clinical questions were formulated using the PICO framework. Systematic literature searches were conducted in PubMed, Embase, and the Cochrane Library for studies published between February 2021 and December 2024. Evidence was appraised using the GRADE methodology, and recommendations were finalized through a modified Delphi consensus process. Twenty recommendations were developed covering disease activity monitoring, non-pharmacological interventions, pharmacological treatment, treatment sequencing, tapering strategies, comorbidity management, surgical interventions, and safety monitoring. Key recommendations include implementation of a treat-to-target strategy, use of Axial Spondyloarthritis Disease Activity Score for disease assessment, smoking cessation and exercise, nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line therapy, and the use of tumor necrosis factor inhibitors, interleukin-17 inhibitors, or Janus kinase inhibitors in patients with active disease refractory to NSAIDs. Recommendations were also provided for treatment selection according to extra-musculoskeletal manifestations and for monitoring treatment-related adverse events. These updated recommendations provide evidence-based guidance for the comprehensive management of axSpA in Korea and aim to improve clinical outcomes, quality of life, and standardization of care.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"255-278"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in systemic lupus erythematosus incidence and prevalence among Korean women of childbearing age: a nationwide study 2011~2020.","authors":"Min Kyung Chung, Jin-Su Park, Hyunsun Lim, In-Woon Baek, Pil Gyu Park, Chan Hee Lee, Jisoo Lee","doi":"10.4078/jrd.2025.0168","DOIUrl":"10.4078/jrd.2025.0168","url":null,"abstract":"<p><strong>Objective: </strong>Despite advances in systemic lupus erythematosus (SLE) care, the disease remains a significant burden for women of childbearing age. This study assessed trends in SLE incidence and prevalence among women of childbearing age from 2011 to 2020, comparing the periods 2011~2015 and 2016~2020.</p><p><strong>Methods: </strong>Women aged 20~49 with SLE were identified from National Health Insurance Service-National Health Information Database (2009~2020). SLE was defined by ICD-10 (International Classification of Disease, 10th revision) code, M32. Incidence and prevalence per 100,000 person-years (PYs) were calculated and stratified by year and age.</p><p><strong>Results: </strong>Between 2011~2020, SLE incidence was 8.2 (95% confidence interval [CI] 8.1 to 8.4)/100,000 PYs, and prevalence 90.6 (95% CI 90.1 to 91.2)/100,000 PYs among women of childbearing age. Incidence remained similar between 2011~2015 and 2016~2020 (8.2 vs. 8.3/100,000 PYs, p=0.403), but prevalence was significantly increased in 2016~2020 compared to 2011~2015 (98.0 vs. 83.5/100,000 PYs, p<0.001). Age-stratified incidence showed a reverse J-shaped distribution, peaking at ages 20~24, then declining and stabilizing through 30~49 years. Age-stratified prevalence followed a bell-shaped curve, peaking at ages 40~44. This incidence pattern remained consistent between 2011~2015 and 2016~2020, but prevalence shifted left in 2016~2020, with a notable increase in the 45~49 age group.</p><p><strong>Conclusion: </strong>The prevalence of SLE among Korean women of childbearing age increased during 2016~2020 compared with 2011~2015, despite stable incidence. This rising prevalence may reflect improved survival associated with advances in disease management.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"295-303"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of synovitis-acne-pustulosis-hyperostosis-osteitis syndrome with robust peripheral arthritis responding to secukinumab.","authors":"Jiaqi Zhang, Ruiyao Hu, Yiqiong Zhang, Naigang Chen, Shiqi Zhang, Shufeng Wei, Chen Li","doi":"10.4078/jrd.2025.0082","DOIUrl":"10.4078/jrd.2025.0082","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"320-322"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Incidence of active tuberculosis in Korean patients with rheumatoid arthritis: a comparison between tumor necrosis factor inhibitors and tofacitinib.","authors":"Jeong-Yeon Kim, Seung-Hun You, Yoon-Kyoung Sung, Sun-Young Jung, Soo-Kyung Cho","doi":"10.4078/jrd.2025.0091C","DOIUrl":"https://doi.org/10.4078/jrd.2025.0091C","url":null,"abstract":"<p><p>[This corrects the article on p. 116 in vol. 33.].</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"323-324"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory analysis of early changes in peripheral immune cell proportions and clinical response following methotrexate and biologic treatment in rheumatoid arthritis.","authors":"Sei Muraoka, Tomohiro Yamada, Nobuyuki Yasuda, Jungo Kakuta, Hiroshi Sato, Satoshi Mizutani, Makoto Kaburaki, Toshio Imai, Toshihiro Nanki","doi":"10.4078/jrd.2025.0182","DOIUrl":"10.4078/jrd.2025.0182","url":null,"abstract":"<p><strong>Objective: </strong>To examine the relationships between changes in the proportions of immune cell populations and clinical response at 2 weeks post-treatment with methotrexate (MTX), tumour necrosis factor (TNF) inhibitors, or abatacept, with treatment efficacy at week 12 in patients with rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>Peripheral blood samples were collected from 30 patients with RA who received MTX (n=10), a TNF inhibitor+MTX (n=10), and abatacept+MTX (n=10) in this observational study. Of these, 25 patients completed the 12-week follow-up and were included in the efficacy and correlation analyses (MTX n=9; TNF inhibitor+MTX n=8; abatacept+MTX n=8). Immune cell phenotypes were determined using 11-colour flow cytometry at baseline and 2 weeks after drug administration.</p><p><strong>Results: </strong>Baseline proportions and changes in several immune cell types at 2 weeks post treatment correlated with the efficacy of arthritis treatment at week 12. Specifically, a higher baseline proportion and a greater decrease at week 2 in class-switched memory B cells following MTX administration were significantly associated with treatment efficacy for arthritis, as were the same changes in activated Th1 cells following abatacept administration. Increases in effector memory CD8+ T cells were also significantly correlated with the efficacy of TNF inhibitor treatment in RA patients.</p><p><strong>Conclusion: </strong>This exploratory study identified a potential association between baseline or early changes in immune cell populations and subsequent clinical responses in RA.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"279-294"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib in chronic non-bacterial osteitis: a potential therapeutic option for multifocal osteitis.","authors":"Vrushal Kale, Sandeep Yadav, Balakrishnan Canchi","doi":"10.4078/jrd.2025.0051","DOIUrl":"10.4078/jrd.2025.0051","url":null,"abstract":"<p><p>Chronic non-bacterial osteitis (CNO) is an autoinflammatory bone disorder with an evolving classification and limited treatment options. It encompasses conditions like SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) syndrome and chronic recurrent multifocal osteomyelitis, which share overlapping clinical and radiological features. While nonsteroidal anti-inflammatory drugs (NSAIDs) serve as first-line therapy, refractory cases require second-line options such as tumor necrosis factor (TNF) inhibitors or bisphosphonates. Emerging evidence suggests Janus kinase inhibitors (JAKis), including tofacitinib, as a viable third-line alternative, though data remains limited. We describe a 16-year-old adolescent male presenting with multifocal osteitis and acneiform lesions, initially classified as SAPHO syndrome but later redefined as CNO based on \"2024 recommendations published in <i>Annals of the Rheumatic Diseases.\"</i> The patient had an inadequate response to NSAIDs, and financial constraints precluded the use of TNF inhibitors or bisphosphonates. Tofacitinib (5 mg twice daily) was introduced as a third-line therapy. Within 8 weeks, the patient showed significant symptom resolution, and magnetic resonance imaging confirmed a reduction in STIR (Short-Tau Inversion Recovery) hyperintense signals. By 6 months, there was complete clinical and radiological remission. This case underscores the reclassification of SAPHO within the broader CNO spectrum and highlights the potential role of tofacitinib as a third-line treatment for refractory CNO. The rapid and sustained response observed suggests that JAKis could be considered in select cases where second-line options are inaccessible. Further research is warranted to establish optimal treatment strategies for this complex condition.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"315-319"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric Antigen Receptor T-cell therapy in systemic lupus erythematosus and other autoimmune diseases: a literature review.","authors":"Faryal Razzaq, Rana Uzair Ahmad, Ahmad Iftikhar, Farva Gondal, Mohammad Ebad Ur Rehman, Muhammad Suhaib, Muhammad Seerat Ali, Ernest Vina, Muhammad Husnain","doi":"10.4078/jrd.2025.0075","DOIUrl":"10.4078/jrd.2025.0075","url":null,"abstract":"<p><p>Autoimmune diseases such as systemic lupus erythematosus (SLE), arise when the immune system inappropriately attacks the body's own tissues, leading to chronic inflammation and significant morbidity. Traditional treatments, including corticosteroids, immunosuppressive drugs, and biologic agents, often provide incomplete disease control and are associated with substantial side effects. Chimeric Antigen Receptor (CAR) T-cell therapy, which targets and eliminates autoreactive B cells, has emerged as a promising novel approach for these conditions. This review evaluates the efficacy, safety, and therapeutic potential of CAR T-cell therapy in SLE and other autoimmune diseases, focusing on recent the most recent clinical studies. The review shows significant clinical improvements and sustained remissions in patients with severe, refractory autoimmune conditions, particularly with CD19 and B Cell Maturation Antigen (BCMA)-targeted CAR T-cell preparations. The review also examines adverse effects and safety profiles, emphasizing the differences in toxicity between cancer patients and those with autoimmune diseases. Overall, the findings highlight the transformative potential of CAR T-cell therapy in autoimmune diseases management, offering new possibilities for more effective and longer-lasting disease control while underscoring the need for further research to optimize therapy protocols and better understand long-term outcomes and safety.</p>","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"238-254"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond purine restriction: dietary quality and sex differences in hyperuricemia.","authors":"Joong Kyong Ahn","doi":"10.4078/jrd.2026.0166","DOIUrl":"10.4078/jrd.2026.0166","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 4","pages":"235-237"},"PeriodicalIF":3.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient sterile polyarthritis following ileostomy reversal in a premature infant.","authors":"Yoonkyo Oh, Su Jin Choi, Doo-Ho Lim","doi":"10.4078/jrd.2025.0060","DOIUrl":"10.4078/jrd.2025.0060","url":null,"abstract":"","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 3","pages":"232-234"},"PeriodicalIF":3.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}